Fenaren

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenaren

Property Description
Active ingredient Diclofenac (Sodium Salt)
Form Tablet, Injection, Suppository, Topical Gel/Patch
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use (General) Relief of pain and reduction of inflammation
Origin Synthetic organic compound (Acetic Acid Derivative)

What Type of Medicine is Fenaren?

Fenaren is a widely recognized medicinal product whose active agent is Diclofenac, which belongs to the pharmacological class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This classification is key as it signifies the drug's primary action is to reduce inflammation, in addition to providing pain relief (analgesic effect) and helping to lower a fever (antipyretic effect). Diclofenac is a synthetic compound derived from phenylacetic acid. As a single-ingredient product, Fenaren is designed to be versatile, typically available in multiple dosage form(s), including tablets for oral use, solutions for injection, and gels for topical preparations, allowing for either systemic or localized therapeutic effect. Diclofenac is used for its effectiveness in acute pain management, with clinical utility across these diverse forms.

Composition and General Purpose of Diclofenac

The core of Fenaren is its sole active ingredient, Diclofenac (usually prepared as the sodium salt), along with other necessary pharmaceutical excipients. The general purpose of this active substance is to help manage symptoms stemming from irritation, heat, swelling, and pain. Diclofenac works by decreasing substances in the body that cause pain and inflammation. This means the medicine generally helps to block the signals that lead to swelling and aches. Diclofenac is utilized for its efficacy in treating pain and inflammatory disorders. This utility confirms its value for patients seeking general relief from underlying inflammation, such as that associated with common rheumatic conditions, thereby improving comfort and mobility.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine

What side effects are possible with Fenaren?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics of Fenaren (Diclofenac) as outlined in government regulatory documents from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

Serious Adverse Reactions (Mandatory Warnings)

Fenaren, like other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), carries documented risks for serious, potentially fatal adverse events:

  • Cardiovascular Thrombotic Events: Increased risk of serious events such as myocardial infarction (MI) and stroke. This risk may occur early in treatment, increases with the duration of use, and is observed most consistently at higher doses.
  • Gastrointestinal Events: Risk of serious events including bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during use and without warning symptoms.

Adverse Reactions by System-Organ Class

The most frequently reported adverse reactions are classified by regulatory agencies as Common (affecting approximately 1% to 10% of users) and often involve the gastrointestinal system or the nervous system:

  • Gastrointestinal Disorders: Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, and flatulence.
  • Nervous System Disorders: Headache and dizziness.
  • General: Edema (fluid retention).

Serious but Rare adverse reactions include severe skin events (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), liver failure, and severe hypersensitivity reactions.

Population-Specific Safety Constraints

Regulatory documents define specific restrictions for certain populations and conditions:

  • Contraindications: Fenaren is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with established congestive heart failure (NYHA Class II-IV).
  • Older Adults: Documented to be at greater risk for serious gastrointestinal adverse events.
  • Pregnancy: Avoid use starting at approximately 30 weeks of gestation due to fetal risk.

Overdose and Emergency Response

Fenaren overdose information, as documented in official regulatory sources, describes the potential for serious manifestations across multiple physiological systems. Documented signs of overdose often include gastrointestinal (GI) disturbances such as nausea, vomiting, diarrhea, and epigastric pain. Central nervous system (CNS) effects are also listed, including drowsiness, headache, dizziness, and tinnitus.

However, regulatory labels emphasize the potential for severe and life-threatening outcomes. These include acute renal failure, which may lead to permanent kidney damage, and serious GI events such as bleeding, ulceration, or perforation, which are documented as potentially fatal. In severe cases, CNS effects can progress to seizures or coma. Elderly patients are noted in official labeling to be at greater risk for more serious consequences, particularly the severe GI events.

Immediate medical attention is a universal requirement in cases of suspected overdose. Official guidance mandates contacting a Poison Control Center or the local emergency number right away. The management of Fenaren overdose is restricted to supportive and symptomatic treatment, as regulatory documents state that no specific antidote is known or available.

Therapeutic Uses of Fenaren

Fenaren (Diclofenac) is commonly used in areas where short-term symptom management is appropriate, primarily addressing symptoms related to inflammatory or irritative states.

Fenaren is relevant in conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in clinical settings that involve acute or disruptive symptom patterns, such as managing post-operative pain or discomfort from trauma like sprains and contusions. Furthermore, it is used for recurrent or episodic manifestations, including specific high-intensity episodes like Primary Dysmenorrhea and acute manifestations of migraine attacks.

“It is relevant for easing symptom clusters that may become intense or disruptive during flare-ups.”

In these scenarios, Fenaren provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.


Quick Fact: Relief for Inflammation and Pain Fenaren is commonly used to help manage the combined symptom cluster of inflammation, swelling, and pain across acute, chronic, and episodic conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Fenaren

Regulatory authorities strictly define the populations eligible to use Fenaren (Diclofenac) based on contraindications and risk factors.

Classification Population Status Defined by Regulators
Absolute Contraindication Known hypersensitivity to Diclofenac or any NSAID (e.g., aspirin-sensitive asthma). Must not use
Absolute Contraindication Active gastrointestinal ulcer, bleeding, or perforation. Must not use
Absolute Contraindication Established congestive heart failure (NYHA II-IV), ischaemic heart disease, or CABG surgery setting. Must not use
Absolute Contraindication Last trimester of pregnancy (ge 30 weeks gestation) or severe hepatic/renal failure. Must not use
Restricted Use Patients with recent Myocardial Infarction (MI), mild-to-moderate organ impairment, or high cardiovascular risk factors. Use is limited and requires close monitoring
Not Established Pediatric population (generally under 18). Safety and effectiveness have not been established

Age and Physiological Constraints: Use is generally established for adults without contraindications. However, geriatric patients are monitored closely due to an increased risk for serious gastrointestinal events. Use during the last trimester of pregnancy is contraindicated, and use during the mid-trimester (20–30 weeks) is limited and requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Fenaren (Diclofenac) is primarily defined by official regulatory statements regarding additive adverse effects and alterations to the clearance of co-administered medicines. The active ingredient's metabolism is primarily mediated by the CYP2C9 enzyme, a pathway relevant to pharmacokinetic interactions.

Regulatory Constraints and Clinically Significant Interactions

Co-administered Product/Class Officially Documented Interaction Outcome
Anticoagulants/Antiplatelet Agents Increased risk of serious bleeding due to additive effects.
Lithium, Digoxin, Methotrexate Fenaren can cause an increase in plasma concentrations of these drugs.
ACE Inhibitors/ARBs/Diuretics Fenaren may reduce the antihypertensive or natriuretic effect of these agents.
Systemic Corticosteroids Increased risk of gastrointestinal ulceration or bleeding.
Other NSAIDs/Analgesic Aspirin Co-administration is generally not recommended due to additive risk of GI events.

Official labeling contraindicates Fenaren use in the treatment of perioperative pain related to Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of allergic reactions to Aspirin or other NSAIDs. Consumption of alcohol is formally cited to increase the risk of stomach bleeding associated with this medicine. Furthermore, regulatory documents note that the risk of renal function deterioration with co-administered ACE Inhibitors/ARBs is heightened in elderly, volume-depleted, or renal-impaired patient populations.

Mechanism of Action

Cyclooxygenase Enzyme Inhibition

The compound acts via multiple mechanisms, starting with the inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2 isoforms). This enzymatic event results in the suppressed synthesis of prostaglandins and other prostanoids, which are eicosanoid mediators in affected biological systems.


Prostanoid Signaling Modulation

This mechanism drives resulting physiological cascade effects. Decreased prostanoid synthesis modulates subsequent signal transduction, maintaining control of pathway activity within specific cellular environments. This action alters signaling sequences that rely on eicosanoid presence for activation.


Non-Prostaglandin Pathway Engagement

The molecule also engages additional mechanisms, including the modulation of the L-arginine nitric oxide-cGMP pathway and the potential inhibition of mediators such as Substance P. These actions influence supplementary systems, resulting in the modulation of signaling patterns within specific pathways.

Dosage and Administration Information

The administration of Fenaren (Diclofenac) emphasizes the use of the lowest effective dosage for the shortest duration necessary. This core principle structures its application across all routes, which include oral tablets, intramuscular (IM) injection, intravenous (IV) infusion, rectal suppositories, and topical gels.


Systemic Dosing and Frequency

Oral dosing regimens for chronic inflammatory conditions, such as Osteoarthritis, typically involve 100 mg to 150 mg daily, taken in divided doses (e.g., two or three times a day). A critical procedural instruction is the maximum total daily systemic dose, which generally must not exceed 150 mg when combining different systemic forms (oral, rectal, or injection). Use of the IM or IV injection forms is typically restricted to acute, severe pain management for a maximum of two days, followed by a transition to oral or rectal administration for continued use.


Administration Conditions

Standard procedures involve specific steps for proper administration. Delayed-release tablets must be swallowed whole and not crushed or chewed to maintain their enteric-coated integrity. These tablets are typically taken with food or milk. Conversely, certain liquid-filled capsules or powders are used on an empty stomach to facilitate rapid absorption. IV administration requires the injection solution to be accurately diluted and buffered immediately prior to infusion. Furthermore, administration in sensitive populations, such as older adults, must be initiated at the lowest available effective dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fenaren (Diclofenac)


Evidence for Use in Inflammatory Joint Conditions: Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS)

Research into Fenaren for chronic inflammatory conditions has primarily used Randomized Controlled Trials (RCTs) and comprehensive meta-analyses to explore how symptom patterns change over time. These studies were conducted with adult populations experiencing pain and functional limitations. For Osteoarthritis (OA), research examined both oral tablets and topical preparations, focusing on measured outcomes like changes in discomfort intensity and functional outcomes describing activity level. Studies focusing on topical forms reported on patterns related to measured short-term outcomes in localized joint discomfort.

For Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), Fenaren was studied to explore symptom patterns associated with conditions characterized by fluctuating or episodic manifestations. Research explored changes in outcomes linked to inflammatory or irritative states, such as joint tenderness and stiffness, and monitored patient-reported outcomes. A key limitation is that evidence is largely focused on symptom patterns and does not provide insight into whether the medicine modifies the underlying disease progression.


Evidence for Use in Acute Pain and Episodic Conditions

For acute or disruptive episodes, the research mainly consists of single-dose, short-term RCTs that examined outcomes related to the speed of symptom change. This includes evidence for acute post-operative pain, primary dysmenorrhea, and acute migraine attacks. For acute pain following surgery, research examined the time intervals associated with patient-reported changes and monitored the time interval until patients required supplementary medication. The key uncertainty is that follow-up durations were limited, confining the findings to the immediate hours following the dose.


What is Still Uncertain About Fenaren

A major research limitation is that the evidence quality varies across studies. Research indicates that findings were mixed regarding the measured outcomes across different formulations for acute pain patterns, as certain salt types were associated with different measured onsets of change. The existing studies provide limited insight into the effectiveness of specific formulations, such as the topical gel, for all affected joints beyond the knee and hand. Furthermore, there is a recognized lack of comparative evidence for long-term outcomes, and data for many special population groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Fenaren (FAQ)


Q: What conditions besides arthritis is Fenaren used to treat?

A: Official product information states that Fenaren (Diclofenac) is approved for relieving the signs and symptoms of Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Beyond these chronic conditions, it is also indicated for the management of acute pain, primary dysmenorrhea (period pain), and acute migraine attacks in certain formulations.


Q: How long can I realistically expect the pain relief from Fenaren to last?

A: Studies on the active ingredient, Diclofenac, show it has a short terminal plasma half-life of approximately 1 to 2 hours. While this describes how quickly the drug leaves the bloodstream, the actual duration of noticeable pain relief can vary among individuals.


Q: Is a mild headache or dizziness normal when first starting Fenaren?

A: Yes, regulatory documents list headache and dizziness among the most frequently reported adverse reactions for oral formulations. They are classified as 'Common' side effects, meaning they are reported in approximately 1% to 10% of users.


Q: Can Fenaren affect liver or kidney function?

A: Yes, official warnings note the risk of Hepatotoxicity (liver damage) and Renal Toxicity (kidney damage). The product label advises that patients with existing kidney or liver impairment are at greater risk, and monitoring of these functions may be necessary, especially for patients at risk.


Q: Does Fenaren interact with blood pressure medications?

A: Yes, Fenaren may interfere with the effects of certain blood pressure medications, such as ACE Inhibitors, ARBs, and diuretics. This could potentially reduce the blood pressure-lowering effect. Taking Fenaren with these medicines may also increase the risk of worsening kidney function.


Q: Is Fenaren safe to use while breastfeeding?

A: Data on Fenaren's excretion into human milk is limited, but the levels are generally reported to be very low. Official guidance advises caution, though low levels have been measured in milk. Use during breastfeeding should be determined by a healthcare provider.


Q: Why do people sometimes need an additional medicine (like misoprostol) when taking Fenaren?

A: Fenaren is sometimes available in a combined formulation with a drug like misoprostol. This combination product is approved for use to help protect the stomach lining and reduce the risk of serious gastrointestinal complications.


Q: What is the typical time frame for Fenaren to start working?

A: For delayed-release oral tablets, official pharmacokinetic data indicates that peak levels of the medicine in the blood are usually reached within 2 hours if taken on an empty stomach. If taken with food, this process can be significantly slower, sometimes taking up to 10 hours for the peak level to occur.


Q: Does Fenaren treat the underlying cause of inflammation or just the symptoms?

A: Fenaren is classified as a symptomatic treatment. Its primary action is to reduce the substances in the body that cause pain and inflammation, providing relief from symptoms like swelling and stiffness. Regulatory documents indicate the medicine does not modify the underlying progression of the disease.


Q: Do the side effects of Fenaren oral tablets differ from the topical gel?

A: Yes, the side effect profiles differ because of absorption rates. The risk of systemic adverse effects (such as cardiovascular or serious GI events) is significantly lower with the topical gel than with oral tablets. However, the topical gel is more likely to cause local adverse reactions like redness, itching, or rash at the application site.


Q: Is it normal to feel more sensitive to the sun while taking Fenaren?

A: Yes, regulatory warnings for certain Diclofenac formulations, particularly the topical gel, advise that they can cause an increased risk of photosensitivity. This means your skin may become more sensitive to light from the sun or tanning beds, potentially leading to severe sunburns or blistering.


Q: What kind of stomach discomfort is generally considered a common side effect of Fenaren?

A: Common gastrointestinal side effects, reported in 1% to 10% of users, include nausea, vomiting, diarrhea, abdominal pain, and dyspepsia (indigestion). These are the typical types of stomach discomfort listed in the regulatory profiles.


Q: What happens if I take Fenaren with alcohol?

A: Official regulatory documents specifically warn that consuming alcohol while using Fenaren can significantly increase the risk of serious stomach bleeding. Regulatory warnings indicate that minimizing alcohol intake is generally recommended while using this medicine.


Q: Are there any known interactions between Fenaren and herbal supplements?

A: While specific interactions with herbal supplements are not always listed in the core regulatory label, government patient resources often emphasize the importance of discussing all herbal remedies and supplements with a healthcare provider. This is because these products may not be fully tested for interactions with prescription medications.


Q: Can children or adolescents use Fenaren?

A: For systemic oral forms, the safety and effectiveness have not been established by many regulatory bodies for the general pediatric population (under 18). Use in this group is generally restricted to specific, approved indications if they exist.


Q: Is there a maximum time frame Fenaren should be used continuously?

A: Regulatory guidance consistently emphasizes that Fenaren should be used at the lowest effective dosage for the shortest duration necessary to achieve treatment goals. This is a core principle to minimize the risk of serious adverse events associated with all NSAIDs.


Q: Does long-term use of Fenaren increase the risk of serious side effects?

A: Yes, regulatory warnings indicate that the risk of serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal events (like bleeding or ulcers) increases with both the duration of use and higher doses of the medicine.


Q: Are there any specific dietary restrictions when taking Fenaren?

A: There are no major specific dietary restrictions; however, regulatory data shows that taking delayed-release tablets with food may cause a delay in how quickly the medicine is absorbed into your body. The overall amount absorbed is generally not significantly affected.


Q: Is Fenaren available over-the-counter in some countries?

A: In many regions, oral Fenaren requires a prescription due to the associated systemic risks. However, some low-dose topical gel formulations are approved for over-the-counter (OTC) sale because their systemic absorption into the bloodstream is significantly lower.


Q: What kind of research has been done on the long-term safety of Fenaren?

A: Regulatory reviews highlight that studies have consistently demonstrated an increased risk of arterial thrombotic events (heart attack, stroke) associated with the use of Fenaren, particularly at high doses and in long-term treatment. These risks are detailed in official warnings.


Q: Are there studies comparing the effectiveness of different formulations of Fenaren (oral vs. topical)?

A: Regulatory documents acknowledge that clinical evidence quality and measured outcomes can vary across different formulations (like oral tablets versus topical gels) for acute pain. The topical gel is primarily studied and generally limited to treating localized joint discomfort.


Q: Is Fenaren used to treat symptoms of a migraine headache?

A: Yes, certain formulations of Fenaren (Diclofenac) are officially approved for the acute treatment of migraine attacks.


Q: Do doctors ever prescribe Fenaren for period pain (dysmenorrhea)?

A: Yes, Fenaren (Diclofenac) is officially indicated for the management of primary dysmenorrhea, which is the medical term for common menstrual cramps or period pain.


Q: What is the mechanism by which Fenaren may cause rebound headaches if used frequently?

A: Patient-facing resources from health authorities note that taking NSAIDs, including Fenaren, too frequently or for prolonged periods to treat headaches can paradoxically lead to a worsening condition known as medication-overuse headaches (sometimes called rebound headaches).


Q: How does Fenaren affect fertility in women?

A: Fenaren may temporarily cause a delay in ovulation and is associated with reversible infertility in women. Regulatory labels recommend that women who are having difficulties conceiving may consider discussing the withdrawal of the medication with their healthcare provider.


Q: What should I do if the topical Fenaren gel causes skin irritation?

A: Official warnings advise that Fenaren, regardless of the formulation, should be discontinued at the first appearance of a skin rash or any other signs of a hypersensitivity reaction. If this occurs, contact a healthcare provider as official warnings advise discontinuation at the first sign of a rash or hypersensitivity reaction.


Q: Can I apply heat or a heating pad to the area where I applied Fenaren gel?

A: The patient counseling information for the topical gel formulation advises patients not to apply external heat (such as a heating pad or thermal wrap) or to cover the application site with an airtight or occlusive dressing.


Q: Can Fenaren be used for general back pain or muscle sprains?

A: Fenaren is indicated for the management of pain, but the specific approved uses for the topical gel are restricted to pain from Osteoarthritis in certain joints like the knee, hand, or foot. For general back pain or sprains, systemic (oral) use may be considered by a prescriber.


Q: Why do some people experience ringing in the ears (tinnitus) when taking Fenaren?

A: Ringing in the ears, known as tinnitus, is a recognized side effect included in the adverse reaction profiles of some NSAID medications, including Fenaren. This side effect may be more likely to occur with higher doses or prolonged periods of use.


Q: Is it normal to feel tired or drowsy after taking Fenaren?

A: While not generally classified as a 'Common' side effect, regulatory labels include terms like somnolence (drowsiness) or fatigue under the less frequent adverse reactions associated with the nervous system. If unexpected or severe drowsiness occurs, it should be addressed by a healthcare provider.


Q: Does Fenaren need to be stored in a special way?

A: Yes, the product should be kept in its original container and stored at controlled room temperature (between 20 C to 25 C). It is important to keep the container tightly closed and to prevent the medicine from freezing.

How should Fenaren be stored and disposed of?

The official requirements for storing and disposing of Fenaren (diclofenac) are designed to maintain the product's stability and ensure household safety, based strictly on regulatory labeling.

Official Storage and Handling

Storage Condition
Store at controlled room temperature from 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C and 30 C.
Do not freeze the medicine.
Keep the medicine in its original container and keep the container tightly closed.
Do not use the product after the expiration date printed on the packaging.
The medicine must be kept out of the reach of children and pets at all times.

Disposal Instructions

Disposal of unused or expired Fenaren must be done according to local regulations for pharmaceutical waste. For specific topical forms, such as patches, the official guidance is to fold the patch so the adhesive side sticks to itself before discarding it to prevent accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenaren found in:

A-Z Index: